AbCellera Biologics Inc.

NasdaqGS:ABCL 株式レポート

時価総額：US$949.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AbCellera Biologics マネジメント

マネジメント 基準チェック /44

AbCellera Biologics'の CEO はCarl Hansenで、 Nov2012年に任命され、 の在任期間は 11.58年です。 の年間総報酬は$ 714.94Kで、 64.3%給与と35.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の19.24%を直接所有しており、その価値は$ 194.10M 。経営陣と取締役会の平均在任期間はそれぞれ2.9年と4.8年です。

主要情報

Carl Hansen

最高経営責任者

US$714.9k

報酬総額

CEO給与比率64.3%
CEO在任期間11.6yrs
CEOの所有権19.2%
経営陣の平均在職期間2.9yrs
取締役会の平均在任期間4.8yrs

経営陣の近況

Recent updates

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

Dec 05

AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy

Oct 18

AbCellera Biologics: I Was Wrong

Aug 20

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

Aug 17
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

AbCellera Biologics: A Buy At Current Prices

Aug 06

CEO報酬分析

AbCellera Biologics の収益と比較して、Carl Hansen の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$147m

Dec 31 2023US$715kUS$460k

-US$146m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$9mUS$450k

US$159m

Sep 30 2022n/an/a

US$248m

Jun 30 2022n/an/a

US$200m

Mar 31 2022n/an/a

US$205m

Dec 31 2021US$9mUS$400k

US$153m

Sep 30 2021n/an/a

US$177m

Jun 30 2021n/an/a

US$197m

Mar 31 2021n/an/a

US$203m

Dec 31 2020US$17mUS$296k

US$85m

Sep 30 2020n/an/a

-US$285k

Jun 30 2020n/an/a

US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$250kUS$177k

-US$2m

報酬と市場: Carlの 総報酬 ($USD 714.94K ) は、 US市場 ($USD 3.39M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Carlの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Carl Hansen (49 yo)

11.6yrs

在職期間

US$714,939

報酬

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Carl Hansen
CEO, President & Chairperson11.6yrsUS$714.94k19.24%
$ 182.8m
Andrew Booth
Chief Financial Officer4.8yrsUS$674.56k0.097%
$ 917.2k
Veronique Lecault
COO & Director5.4yrsUS$650.59k3.24%
$ 30.8m
Tryn Stimart
Chief Legal Officer4.8yrsUS$667.69k0.00017%
$ 1.6k
Marcie Thiessen
Senior Director of Finance & Accountingno dataデータなしデータなし
Ester Falconer
Chief Technology Officer3.4yrsデータなしデータなし
Kathleen Reid
Head of Corporate Communicationsless than a yearデータなしデータなし
Graham Craig
Director of Corporate Development1.4yrsデータなしデータなし
Murray McCutcheon
Senior Vice President of Partnering1.4yrsデータなしデータなし
Neil Aubuchon
Chief Commercial Officer2.4yrsUS$5.61m0.016%
$ 156.3k
Adam Clarke
Senior Vice President of Discoveryno dataデータなしデータなし
Paul Colussi
Site Head & VP of Complex Membrane Protein Technologies1.4yrsデータなしデータなし

2.9yrs

平均在職期間

49.5yo

平均年齢

経験豊富な経営陣: ABCLの経営陣は 経験豊富 であると考えられます ( 2.9年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Carl Hansen
CEO, President & Chairperson11.6yrsUS$714.94k19.24%
$ 182.8m
Veronique Lecault
COO & Director5.8yrsUS$650.59k3.24%
$ 30.8m
Michael Hayden
Independent Lead Director4.8yrsUS$105.00k0.49%
$ 4.7m
John Montalbano
Independent Non-Employee Director3.6yrsUS$77.50k0.031%
$ 294.0k
Wen-Chaun Lo
Independent Director2.5yrsUS$55.00k0%
$ 0

4.8yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: ABCLの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。